CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

Core Insights - CERo Therapeutics Holdings, Inc. is presenting promising preclinical results for its lead compound CER-1236 in ovarian cancer at the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors [1] - The study demonstrated that CER-1236 effectively targets ovarian cancer cells without causing toxicity in animal models [2] - The CEO of CERo highlighted the efficacy and safety profile of CER-1236, indicating its potential utility across various cancer types, including ovarian and Non-Small Cell Lung Cancers [3] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that combines innate and adaptive immunity [4] - The company aims to redirect patient-derived T cells to eliminate tumors through a novel cellular immunotherapy platform, referred to as Chimeric Engulfment Receptor T cells (CER-T) [4] - CERo plans to initiate clinical trials for CER-1236 in 2025, targeting both hematological malignancies and solid tumors [4]